Spire (US) launches Spi-Polymer surface treatment:
This article was originally published in Clinica
Spire (US) has developed the Spi-Polymer process which reduces biofouling on the surface of polymeric components of IVD assay devices. The surface treatment is applied to devices using ion implantation technology, providing a more hydrophilic surface which reduces blood cell, air bubble and plasma protein adherence. The reduction of biofouling improves accuracy for diagnostic assay systems by enhancing flow performance and reducing maintenance, says Spire.
You may also be interested in...
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.